What is another name for ipratropium bromide inhalation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Atrovent

Ipratropium bromide inhalation is also known by the brand name Atrovent. 1

Brand Name and Formulations

The FDA-approved brand name for ipratropium bromide is Atrovent, manufactured by Boehringer-Ingelheim. 1 This anticholinergic bronchodilator is available in multiple formulations:

  • Atrovent nasal spray in 0.03% and 0.06% concentrations for rhinorrhea 1
  • Atrovent inhalation solution for nebulization (0.02% solution) 2
  • Atrovent metered-dose inhaler (MDI) at 18 mcg per puff 3

Chemical Classification

Ipratropium bromide is chemically described as a quaternary ammonium muscarinic receptor antagonist, structurally related to atropine but with reduced systemic absorption due to its quaternary structure. 1, 2 The generic name "ipratropium bromide" and brand name "Atrovent" are used interchangeably in clinical practice and medical literature.

Combination Products

When combined with albuterol (a short-acting beta-2 agonist), the product is marketed as Combivent or DuoNeb, containing both ipratropium bromide and albuterol in fixed-dose combinations. 3, 4

The term "Atrovent" remains the most widely recognized alternative name for ipratropium bromide inhalation in clinical practice.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.